Sökning: WFRF:(Yilmaz T)
> (2005-2009) >
Chronomodulated cap...
Chronomodulated capecitabine in combination with short-time oxaliplatin : A Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil
-
- Qvortrup, C. (författare)
- Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, Odense C 5000, Denmark, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
-
- Yilmaz, M. (författare)
- Department of Oncology, Aalborg University Hospital, Aalborg, Denmark
-
- Ogreid, D. (författare)
- Department of Oncology, Rogaland Central Hospital, Stavanger, Norway
-
visa fler...
-
- Berglund, Åke (författare)
- Uppsala universitet,Enheten för onkologi,Ake Berglund
-
- Balteskard, L. (författare)
- Department of Oncology, Tromso University Hospital, Tromso, Norway
-
- Ploen, J. (författare)
- Department of Oncology, Vejle Hospital, Vejle, Denmark
-
- Fokstuen, T. (författare)
- Department of Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden
-
- Starkhammar, Hans (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US
-
- Sorbye, H. (författare)
- Sørbye, H., Department of Oncology, Haukeland University Hospital, Bergen, Norway
-
- Tveit, K. (författare)
- Department of Oncology, Ullevål University Hospital, Oslo, Norway
-
- Pfeiffer, P. (författare)
- Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, Odense C 5000, Denmark
-
visa färre...
-
Department of Oncology, Odense University Hospital, Sdr Boulevard 29, Odense C 5000, Denmark, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark Department of Oncology, Aalborg University Hospital, Aalborg, Denmark (creator_code:org_t)
- Elsevier BV, 2008
- 2008
- Engelska.
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 19:6, s. 1154-1159
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC). Chronomodulation might reduce toxicity and improve efficacy. Patients and methods: A phase II study examining chronomodulated XELOX30 (XELOX30chron): oxaliplatin: 130 mg/m2 on day 1, as a 30-min infusion between 1 and 3 p.m. Capecitabine: total daily dose of 2000 mg/m2, 20% of the dose between 7 and 9 a.m. and 80% of the dose between 6 and 8 p.m. in patients with mCRC resistant to irinotecan. Seventy-one patients were enrolled. Response rate was 18%, median progression-free survival 5.1 months and median overall survival (OS) 10.2 months. Platelet count and performance status were significantly correlated to OS in multivariate analyses. Neurotoxicity grade 2 and 3 was seen in 25% and 2% of patients, respectively, other grade 3 toxic effects were as follows: nausea 6%, vomiting 3%, diarrhoea 12% (3% experienced grade 4) and palmoplantart erytem 9%. Conclusion: XELOX30chron is a convenient second-line regimen with efficacy and safety profile similar to other oxaliplatin schedules. To further investigate chronomodulated XELOX, we have started a Nordic randomised phase II study comparing XELOX30 and XELOX30chron as first-line therapy in patients with mCRC. © The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Nyckelord
- Capecitabine
- Chronotherapy
- Metastatic colorectal cancer
- Oxaliplatin
- Short-time infusion
- XELOX
- NATURAL SCIENCES
- NATURVETENSKAP
- MEDICINE
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Qvortrup, C.
-
Yilmaz, M.
-
Ogreid, D.
-
Berglund, Åke
-
Balteskard, L.
-
Ploen, J.
-
visa fler...
-
Fokstuen, T.
-
Starkhammar, Han ...
-
Sorbye, H.
-
Tveit, K.
-
Pfeiffer, P.
-
visa färre...
- Artiklar i publikationen
-
Annals of Oncolo ...
- Av lärosätet
-
Linköpings universitet
-
Uppsala universitet